Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1

Conditions

Carcinoma, Non-Small-Cell Lung 18Melanoma 16Triple Negative Breast Neoplasms 13Colorectal Neoplasms 11Neoplasms 9Neoplasm Metastasis 9Squamous Cell Carcinoma of Head and Neck 7Pancreatic Neoplasms 7Carcinoma, Renal Cell 7Stomach Neoplasms 6Lymphoma 6Uterine Cervical Neoplasms 5Ovarian Neoplasms 5Lung Neoplasms 4Liver Neoplasms 4Head and Neck Neoplasms 4Esophageal Squamous Cell Carcinoma 4Esophageal Neoplasms 4Endometrial Neoplasms 4Breast Neoplasms 4Small Cell Lung Carcinoma 3Sarcoma 3Nasopharyngeal Carcinoma 3Colonic Neoplasms 3Carcinoma, Hepatocellular 3Advanced Solid Tumor 3Solid Tumors 2Solid Tumor, Adult 2Recurrence 2Rectal Neoplasms 2

Interventions

Brentuximab Vedotin 20Rituximab 10pirtobrutinib 7dacetuzumab 7Doxorubicin 6ruxolitinib 5Vincristine 5Prednisone 5Lenalidomide 5Cyclophosphamide 5ponatinib 4Imatinib Mesylate 4Dexamethasone 4Bendamustine Hydrochloride 4Azacitidine 4nilotinib 3lintuzumab 3Bortezomib 3vosaroxin 2venetoclax 2spartalizumab 2pomalidomide 2ibrutinib 2Rifampin 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2KW-2478 2Ifosfamide 2Gemcitabine 2Etoposide 2Dacarbazine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Hematologic Diseases × spartalizumab × Clear all
NCT03066648 2025-05-18

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Novartis

Phase 1 Completed
241 enrolled
MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Preleukemia, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03111992 2022-02-09

Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

Novartis

Phase 1 Completed
26 enrolled
Plasma cell

Hematologic Diseases, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡